# Efficacy of Early Administration of Tocilizumab in COVID-19 Patients

> **NCT04346355** · PHASE2 · TERMINATED · sponsor: **Azienda USL Reggio Emilia - IRCCS** · enrollment: 126 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04346355
- **Lead sponsor:** Azienda USL Reggio Emilia - IRCCS
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-31
- **Primary completion:** 2020-06-06
- **Final completion:** 2020-06-06
- **Target enrollment:** 126 (ACTUAL)
- **Why stopped:** Based on interim analysis for futility and given an enrolment rate almost nil
- **Last updated:** 2020-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04346355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04346355, "Efficacy of Early Administration of Tocilizumab in COVID-19 Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04346355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*